Drugs / Shenlingcao Oral Liquid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05684952 | May 2023 → Jan 2024 | long COVID-19 | Hong Kong Baptist University | Unknown | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT03712969 | Nov 2018 → Mar 2022 | non-small cell lung carcinoma | West China Hospital | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shenlingcao Oral Liquid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03712969 ↗ |
| Known as | SOL | “Shenlingcao oral liquid (SOL) as a complementary treatment in this patients is lacking at present.” PMID 36871476 ↗ Feb 2023 |
| Modality | Traditional medicine (herbal / TCM) | “Chinese herbal medicine (Shenlingcao oral liquid)” NCT05684952 ↗ |
| Route | Oral | “Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy” NCT03712969 ↗ |